The number of telehealth companies offering GLP-1 medications has exploded since 2023. Some are well-run operations with real clinical oversight. Others are little more than intake forms connected to a prescription pad. The difference between the two can be difficult to spot from a landing page — and the consequences of choosing the wrong one range from wasted money to genuine safety risks.
After the FDA issued warning letters to more than 70 telehealth companies in the past year for misleading marketing practices, the need for consumers to do their own due diligence has never been clearer. This guide walks you through a practical verification process, step by step.
Why Verification Matters More in 2026
The telehealth GLP-1 market is in a transitional moment. The drug shortages that originally drove consumers toward compounded alternatives have largely resolved — both Novo Nordisk and Eli Lilly report that their brand-name products are in full supply. Meanwhile, the FDA is actively enforcing against companies that blur the line between compounded and FDA-approved products, and Novo Nordisk has initiated legal action against at least one major telehealth company over compounded oral semaglutide.
None of this means telehealth is a bad way to access GLP-1 medications. Many patients genuinely benefit from the convenience and accessibility of telehealth prescribing, and there are platforms doing this responsibly. But the landscape is shifting fast enough that a provider that was operating normally six months ago may have changed its practices, its pharmacy partners, or its regulatory status. Verification isn't paranoia — it's good health literacy.
The Verification Checklist
Confirm Whether You're Getting FDA-Approved or Compounded Medication
This is the most fundamental question, and the answer should be obvious on the provider's website. FDA-approved GLP-1 medications for weight loss include Wegovy (semaglutide injection), Zepbound (tirzepatide injection), the Wegovy oral tablet, and Foundayo (orforglipron). Compounded versions of semaglutide or tirzepatide are prepared by compounding pharmacies and have not been evaluated by the FDA for safety or effectiveness.
Both can be legitimate options, but you need to know which one you're getting. If the website is vague about this distinction — or if it takes more than a minute to figure out — that's your first warning sign.
Identify Your Prescriber
A legitimate telehealth platform will connect you with a licensed physician, nurse practitioner, or physician assistant who conducts a medical evaluation before prescribing. You should be able to learn who your prescriber is and verify their credentials.
Every state medical board maintains a searchable license verification database. Search for your prescriber by name to confirm they hold an active, unrestricted license in your state. Telehealth providers are generally required to be licensed in the state where the patient is located — not just where the provider is physically sitting.
Where to check: Search "[your state] medical board license verification" to find your state's database. The Federation of State Medical Boards also maintains a directory at docinfo.org.
Verify the Compounding Pharmacy (If Applicable)
If your medication is compounded, the telehealth platform should be transparent about which pharmacy prepares it. There are two types of compounding pharmacies that matter here:
503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on specific prescriptions. They are primarily regulated by state boards of pharmacy.
503B outsourcing facilities operate under more direct FDA oversight. They can compound medications in larger quantities without individual prescriptions but must register with the FDA, report adverse events, and submit to FDA inspections. The FDA maintains a searchable list of registered 503B facilities on its website.
If your telehealth provider won't tell you which pharmacy compounds your medication, or if you can't verify that pharmacy through state or federal databases, that's a significant transparency gap.
Check for FDA Warning Letters
The FDA publishes all warning letters on its website. You can search by company name to see if your telehealth provider — or its affiliated pharmacy — has received any regulatory action.
A warning letter doesn't automatically mean a company is dangerous, but it does mean the FDA identified specific violations that required correction. If a warning letter was issued months ago and the company's website still shows the same marketing language the FDA objected to, that's a poor sign.
Where to check: FDA Warning Letters Database
Evaluate the Medical Intake Process
The quality of the medical evaluation before prescribing is one of the strongest indicators of a platform's legitimacy. Consider what you were asked and how:
A thorough intake should include your complete medical history, current medications, allergies, relevant lab work or recent physical exam findings, and specific contraindications for GLP-1 medications (personal or family history of medullary thyroid carcinoma, history of pancreatitis, Multiple Endocrine Neoplasia syndrome type 2, among others).
If the intake felt more like a shopping checkout than a medical evaluation — a few basic questions, no interaction with a clinician, and a prescription within minutes — the platform may be prioritizing volume over clinical appropriateness.
Assess Follow-Up and Continuity of Care
GLP-1 medications require dose titration — starting at a low dose and gradually increasing over weeks or months to manage side effects and find the effective dose for each patient. This process requires clinical oversight.
Check whether the platform provides structured follow-up during titration, ongoing access to your prescriber for questions or concerns, a clear process for reporting side effects, and guidance on what to do if you need to stop the medication or switch to a different one.
A platform that's primarily designed for the initial transaction, with minimal follow-up infrastructure, may not be equipped to support you through the full course of treatment.
Review the Pricing Structure
Legitimate pricing for GLP-1 telehealth services varies, but understanding the components helps you spot anomalies:
Consultation fees typically range from $0 (bundled into the subscription) to $99 for an initial visit. Follow-up visits may be additional.
Compounded medication generally costs between $150 and $400 per month, depending on the dose and formulation.
Brand-name medication costs are higher — often $300+ per month with manufacturer savings programs, or $1,000+ at list price — but may be partially covered by insurance.
Be cautious of prices that seem dramatically below market rates. The compounding pharmacy has real costs — pharmaceutical-grade ingredients, sterile preparation, quality testing, licensed pharmacist oversight — and extreme discounts may reflect corners being cut somewhere in that process.
Look for Clinical Transparency
Does the platform publish information about its clinical approach? Trustworthy providers typically describe their prescribing criteria, how they handle contraindications and drug interactions, their dose titration protocols, which clinical guidelines they follow, and how they monitor patient outcomes.
This doesn't need to be a peer-reviewed publication — even a well-written FAQ or clinical approach page demonstrates that the company takes its clinical responsibilities seriously.
Specific Things That Should Not Worry You
Consumer protection means knowing what to worry about — and what not to. Here are common concerns that are generally not red flags on their own:
"They don't have a physical office I can visit." Telehealth is, by definition, remote. Many excellent telehealth platforms operate entirely online. The absence of a brick-and-mortar location is not a concern — the presence of licensed clinicians and transparent operations is what matters.
"My medication comes in the mail." Mail-order pharmacy is a standard, well-regulated component of American healthcare. It's how millions of people receive prescription medications, and it's subject to the same state and federal pharmacy regulations as in-person dispensing.
"The company is relatively new." The telehealth GLP-1 market is inherently young — most companies in this space launched in the past three years. Newness is not a disqualifying factor if the company demonstrates clinical rigor, regulatory compliance, and transparent operations.
When to Consider Switching Providers
Some situations warrant finding a different telehealth provider:
Your provider has received an FDA warning letter and has not visibly corrected the issues. You cannot verify the identity or licensing of the clinician who prescribed your medication. The platform has changed its pharmacy partner without notifying you or explaining why. You're experiencing side effects and cannot get timely clinical guidance. Your medication's labeling has changed, or you notice inconsistencies in the product you receive.
Switching providers doesn't mean starting your treatment over. Your prescription history, current dose, and medical records should transfer to a new provider. A responsible platform will facilitate that transition if you request it.
Quick Reference: Verification Resources
Prescriber licensing: Your state medical board (search "[state] medical board license verification") or docinfo.org
Pharmacy licensing: Your state board of pharmacy (search "[state] board of pharmacy license lookup")
503B outsourcing facilities: FDA Registered Outsourcing Facilities List
FDA warning letters: FDA Warning Letters Database
BBB complaints: Better Business Bureau